Logo image
Update on Charcot-Marie-Tooth disease
Journal article   Peer reviewed

Update on Charcot-Marie-Tooth disease

Agnes Patzkó and Michael E Shy
Current neurology and neuroscience reports, Vol.11(1), pp.78-88
02/2011
DOI: 10.1007/s11910-010-0158-7
PMCID: PMC3685483
PMID: 21080241

View Online

Abstract

Charcot-Marie-Tooth disease (CMT) disease encompasses a genetically heterogeneous group of inherited neuropathies, also known as hereditary motor and sensory neuropathies. CMT results from mutations in more than 40 genes expressed in Schwann cells and neurons causing overlapping phenotypes. The classic CMT phenotype reflects length-dependent axonal degeneration characterized by distal sensory loss and weakness, deep tendon reflex abnormalities, and skeletal deformities. Recent articles have provided insight into the molecular pathogenesis of CMT, which, for the first time, suggest potential therapeutic targets. Although there are currently no effective medications for CMT, multiple clinical trials are ongoing or being planned. This review will focus on the underlying pathomechanisms and diagnostic approaches of CMT and discuss the emerging therapeutic strategies.
Diagnosis, Differential Phenotype Genetic Testing Humans Charcot-Marie-Tooth Disease - therapy Charcot-Marie-Tooth Disease - physiopathology Mutation Charcot-Marie-Tooth Disease - pathology Genetic Counseling Charcot-Marie-Tooth Disease - genetics

Details

Logo image